Ashland is introducing Klucel EXF Ultra HPC, an ultra-fine particle size, premier tablet binder during CPhI North America.
Pharmaceutical manufacturers continue to search for solutions that save costs and ensure formulation predictability, reliability and robustness. Klucel EXF Ultra HPC exhibits binder efficiency, compressibility and plasticity with enhanced tablet strength and low friability at usage levels as low as 1-2%.
A growing concern for geriatric and pediatric patient populations continues to be swallowability. This new tablet binder aims to tackle this concern, providing lower use levels that enable manufacturers to create smaller, easier-to-swallow tablets. Additional features including enhanced hardness and improved friability may also enable cost savings through potential reductions in defect rates.
“We are excited to add Klucel EXF Ultra HPC to our tablet binder portfolio for oral solid dosage formulations,” said Thomas Hanson, global business manager of pharmaceutical specialities at Kentucky-based Ashland. “Binders are an essential element in the formulation of tablets, and Ashland solvers are dedicated to answering the toughest challenges.”
Ashland introduced hydroxypropylcellulose (HPC), an excipient that changed the oral drug delivery model, to the market over 65 years ago. This latest endeavour further progresses the excipients market.
